Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 18/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 18/20 | 0.65 |
| ▸ | PDE4A | P27815 | 4/20 | 0.59 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14691218 | 0.88 | PDE4B (0.67) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL29682915 | 0.88 | PDE4B (0.69) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL23499796 | 0.88 | PDE4B (0.69) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL14705272 | 0.87 | PDE4B (0.71) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL14691102 | 0.87 | PDE4B (0.69) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL29682762 | 0.87 | PDE4B (0.79) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL23499687 | 0.87 | PDE4B (0.79) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL14691174 | 0.87 | PDE4B (0.81) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL23499703 | 0.86 | PDE4B (0.77) | PDE4BPDE4DPDE4APDE4CABCB11 | |
| SCHEMBL29682553 | 0.86 | PDE4B (0.77) | PDE4BPDE4DPDE4APDE4CABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126933-B2 | Soft PDE4 inhibitors | AMAKEM NV (BE) | 2015-09-08 | — | — | US | disclosed |
| US-20140187555-A1 | NOVEL SOFT PDE4 INHIBITORS | AMAKEM NV (BE) | 2014-07-03 | — | — | US | disclosed |
| WO-2013021021-A1 | NOVEL SOFT PDE4 INHIBITORS | AMAKEM NV (BE) | 2013-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187555-A1 | NOVEL SOFT PDE4 INHIBITORS | PDE4A, PDE4B, PDE12 | PDE4B 2/4885PDE4D 5/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.